Hyundai Pharmaceutical Co Ltd
KRX:004310
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3 000
13 550
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| KR |
|
Hyundai Pharmaceutical Co Ltd
KRX:004310
|
300.8B KRW |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
964.8B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.9B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
268.4B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.9B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
219B CHF |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
267.4B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
149.5B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
94.6B EUR |
Loading...
|
Market Distribution
| Min | -163 055.6% |
| 30th Percentile | -2.2% |
| Median | 2.7% |
| 70th Percentile | 6.8% |
| Max | 22 874.8% |
Other Profitability Ratios
Hyundai Pharmaceutical Co Ltd
Glance View
Hyundai Pharmaceutical Co., Ltd. engages in the manufacturing and distribution of pharmaceutical products, health food drinks and medical equipment. The company is headquartered in Cheonan, Chungcheongnam-Do and currently employs 378 full-time employees. The firm mainly provides two categories of products: pharmaceuticals, including ophthalmological tablets, clopidogrel bisulfate, mirtazapine tablets and others, which are applied in the treatment of depressive disorder, hypertension, hemostatics and others, as well as healthcare food products, including vitamin products, calcium supplements and others. The company also provides dietary various beverages and medical equipment. The firm mainly distributes its products within domestic market. In addition, the Company also involves in the leasing business.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Hyundai Pharmaceutical Co Ltd is 1.1%, which is below its 3-year median of 2.1%.
Over the last 3 years, Hyundai Pharmaceutical Co Ltd’s Operating Margin has decreased from 3.4% to 1.1%. During this period, it reached a low of -1% on May 31, 2025 and a high of 5.1% on May 31, 2023.